Xavier Lahaye

Xavier Lahaye is a CNRS Research Fellow and Permanent researcher at Institut Curie in Paris, France, where he leads the Innate immunity team within the Immunity and Cancer unit (U932).

His research integrates immunology, cancer biology, and virology with focus on innate immune mechanisms against viral pathogens. Key investigations include nuclear membrane proteins in HIV restriction, dendritic cell responses to vaccines, and extracellular vesicle-based therapeutics for SARS-CoV-2. His work employs single-cell analysis and molecular virology to dissect host-pathogen interactions in cancer and infection contexts.

Analysis of his 2020-2021 publications reveals a trajectory toward therapeutic applications of basic immunology discoveries, particularly in viral entry inhibition and vaccine response modulation. His SARS-CoV-2 vesicle research demonstrates translational potential for pandemic countermeasures.

No scientific awards are documented in the provided materials.

Dr. Lahaye operates within the interdisciplinary Immunity and Cancer unit, which bridges fundamental immunology and oncology research through collaborations across Institut Curie's research divisions.